Medically Integrated. Patient-Centered.

Oncology Optimized Limited Distribution:

The NCODA-Preferred Model for Patient-Centered Medically Integrated Oncology Care

Jonas M. Congelli, RPh

Associate Executive Director, NCODA

Douglas Braun, PharmD, CSP

Sr Mgr, Partner Development & Strategy, NCODA

NCODA

Distribution Models

NCODA defines four primary models within the oncology distribution landscape:

- Open Distribution
- Closed Distribution
- PBM Influenced Limited Distribution
- NCODA Optimized Limited Distribution (OOLD)

What is OOLD?

Represents the NCODA preferred distribution model, where PBM-affiliated mail order pharmacies are excluded, and MIPs and non-PBM affiliated pharmacies can dispense. This model enables coordinated, in-practice care and supports timely, patient-centered treatment.

NCODA

Importance of OOLD to Practice/Members

The ability for a Medically Integrated Practice to dispense oncology medications to patients cannot be understated.

Having direct access to the EHR, the oncologist and the patient allows the pharmacy/dispensing team to:

- Perform complete clinical reviews
- Align fills to minimize multiple trips to the clinic
- Make interventions where appropriate
- Monitor labs/notes/pathologies to ensure fills are appropriate with respect to timing/dose/etc.

Importance of OOLD to Practice/Members

All of this translates to:

- Higher level of oncology care to the patient
- Comprehensive care from the patient's oncology team
- Faster Turnaround time to providing meds to patients.
- Increased adherence and compliance
- Increased monitoring/management of ADEs to potentially reduce hospitalizations
- Increased patient satisfaction
- Reduced waste
- Higher capture rates at the practice => Increased revenue for the practice

IntrinsiQ Data on LDD Capture Rates

Table 1. Limited Distribution Models: Percent Capture Rate

This table describes the total dispenses captured and % capture rate organized by drug, network description and fill type.

Group/Drug	Network Description	Internal Fills	External Fills	% Internal Capture
Network 1	2 non-PBM SPs + Physician/Hospital MIDs	8385	1028	**89.08%**
Zanubrutinib		3994	413	90.63%
Acalabrutinib		4391	615	87.71%
Network 2	2 non-PBM SPs + 1 PBM SP + Physician/Hospital MIDs	9008	1986	**81.94%**
Venetoclax		3738	592	86.33%
Ibrutinib		5270	1394	79.08%
Network 3	Open non-PBM SPs + 3 PBM SPs + Physician/Hospital MIDs	9089	5952	**60.43%**
Enzalutamide		6048	2648	69.55%
Abemaciclib		3041	3304	47.93%

OOLD!

NCODA

- Maximizing Prescription Capture Rates at Medically Integrated Dispensing Sites: The Role of Limited Specialty Network in OncologyModels

The ~~3~~ 4 Considerations of Drug Selection

1. Efficacy
2. Safety
3. Cost/Practice Economics
4. **DISTRIBUTION!**

OOLD Supports the Medically Integrated Practice Model!

NCODA

SUMMARY

- Oncology Optimized LDDs promote coordinated, in-practice care and ensures timely, patient-centered treatment
- Work with your pharma partners and GPO to ensure you have access to OOLDs
- When talking to pharma, stress the importance of limiting the access of their medications to OOLD
- If you receive a rejection for an OOLD, call the PBM and attempt to obtain an override to dispense

QUESTION & ANSWER

Oncology Optimized Limited Distribution:

The NCODA-Preferred Model for Patient-Centered Medically Integrated Oncology Care

Jonas M. Congelli, RPh

Associate Executive Director, NCODA

Douglas Braun, PharmD, CSP

Sr Mgr, Partner Development & Strategy, NCODA